PFE Mar 2025 22.500 call
| Previous close | 5.15 |
| Open | 5.66 |
| Bid | 5.60 |
| Ask | 6.95 |
| Strike | 22.50 |
| Expiry date | 2025-03-21 |
| Day's range | 5.66 - 5.66 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.16k |
ZacksPfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
Barrons.comMerck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.
Business WirePfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK, June 18, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning.
